| Document |
Document Title |
|
WO/2022/117877A1 |
The present invention provides cyclic tetrapeptides consisting of alternating α- and β-amino acids and metal complexes thereof. The cyclic tetrapeptides are particularly useful for coordinating a metal selected from Pb, Cd, Hg and As. ...
|
|
WO/2022/111605A1 |
The present disclosure relates to an aryl or heteroaryl substituted 5-membered aromatic heterocyclic compound and the use thereof. In particular, provided is a compound as shown in formula I or a pharmaceutically acceptable salt thereof,...
|
|
WO/2022/106669A1 |
The invention relates in particular to a process for the preparation of a compound of formula (I) wherein R1 and R2 are as defined in the description and in the claims.
|
|
WO/2022/106633A1 |
The present disclosure relates to the synthesis of prostate specific membrane antigen (PSMA) ligands that are useful in the treatment of diseases like cancer. In particular, the disclosure relates to a method for synthesizing PSMA ligand...
|
|
WO/2022/106629A1 |
The present disclosure relates to the synthesis of prostate specific membrane antigen (PSMA) ligands that are useful in the treatment of diseases like cancer. In particular, the disclosure relates to a method for synthesizing PSMA ligand...
|
|
WO/2022/100696A1 |
Disclosed in the present application are a multi-specific bioconjugate linker and a synthetic method therefor, and specifically, a compound or a tautomer, a mesomer, a racemate, an enantiomer, or a diastereoisomer thereof, or a mixture t...
|
|
WO/2022/103827A1 |
Disclosed herein are methods of treating a cancer that overexpresses NQOl comprising administering KP372-1. In some embodiments, KP372-1 is administered with a polymerase inhibitor.
|
|
WO/2022/095965A1 |
Disclosed in the present invention is a tetrazole derivative having a structure represented by a general formula I. Also disclosed in the present invention are a composition containing the tetrazole derivative and an application of the t...
|
|
WO/2022/085571A1 |
A method for producing a radioactive zirconium complex according to the present invention comprises a step for reacting a radioactive zirconium ion, a ligand compound comprising DOTA or a DOTA derivative and an additive such as hydroxybe...
|
|
WO/2022/076563A1 |
The instant invention describes macrocyclic compounds having antiproliferation activity, and methods of treating disorders such as cancer, tumors and cell proliferation related disorders.
|
|
WO/2022/074673A1 |
A tetra-aza corand compound of formula (Ia) and compound of formula (Ib) and salts thereof. The tetra-aza corand of formula (Ia) and (Ib) of the present invention relates to novel corand entity having a substantially enclosed volume and ...
|
|
WO/2022/072374A1 |
Disclosed herein, inter alia, is a light-controlled bioorthogonal tetrazine ligation.
|
|
WO/2022/067082A1 |
The present invention provides a fused heteroaryl compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ven...
|
|
WO/2022/061193A1 |
Provided are vitamin D3 derivatives of formula (I), pharmaceutical compositions thereof, and pharmaceutical or medical uses thereof for treating metabolic disease, a liver disease, obesity, diabetes, cardiovascular disease, or cancer in ...
|
|
WO/2022/058733A1 |
The present invention relates to compounds for stabilising the native tetrameric form of transthyretin and protecting it from proteolytic cleavage; compounds for use in the prevention and treatment of transthyretin amyloidosis; and agent...
|
|
WO/2022/023240A1 |
The invention relates to a process for the preparation of dimeric contrast agents for use in Magnetic resonance Imaging (MRI), in particular [μ-[1-[bis[2-(hydroxy-kO)-3- [4,7,10-tris[(carboxy-kO)methyl]-1,4,7,10-tetraazacyclododec
-1-yl...
|
|
WO/2022/016345A1 |
Disclosed is an application of a composition for preventing and/or eliminating platelet aggregation in an in vitro blood sample. The composition comprises at least one compound selected from the group consisting of formula (I) and a salt...
|
|
WO/2022/005998A1 |
The present disclosure provides compositions and methods for the detection and treatment of cancer. Specifically, the compositions of the present technology include novel compounds that may be complexed with a radioisotope. Also disclose...
|
|
WO/2021/250163A1 |
The present invention refers to a process for obtaining gadoterate meglumine from high purity tetraxetan (DOTA) which does not require the use of organic solvents and optimizes the conditions of the synthetic process. The tetraxetan from...
|
|
WO/2021/251551A1 |
The present invention relates to a compound of formula 1 and a pharmaceutical composition containing same. This compound may be useful as: a therapeutic agent for degenerative brain diseases including dementia or cranial nerve diseases a...
|
|
WO/2021/252640A1 |
The present disclosure relates to compounds of formulas (A) and (I), pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, pharmaceutical compositions comprising the same, methods of preparing the same, interme...
|
|
WO/2021/247634A1 |
Provided herein are compounds of Formula (I''), Formula (I'), Formula (I), Formula (II'), and Formula (II), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labele...
|
|
WO/2021/228992A1 |
The present invention relates to novel tetrazine compounds for use in pretargeted in vivo imaging and in therapy and to the precursors of the tetrazine compounds. The compounds are suitable for use in click chemistry, i.e. reactions that...
|
|
WO/2021/209383A1 |
The present invention related to compounds of Formula (I) or an agronomically acceptable salt thereof, wherein Q, R2, R3, R4 and R5 are as described herein. The invention further relates to compositions comprising said compounds, to meth...
|
|
WO/2021/204666A1 |
The invention relates to isophthalic acid diamides having general formula (I) as herbicides. In this formula (I), X and Y represent radicals such as hydrogen, alkyl and halogen. Z1 and Z2 represent radicals such as alkyl, cycloalkyl and ...
|
|
WO/2021/204669A1 |
The invention relates to substituted isophthalic acid diamides and to their use as herbicides. Disclosed are isophthalic acid diamides having general formula (I) as herbicides. In this formula (I), Z1 and Z2 represent radicals such as al...
|
|
WO/2021/204667A1 |
The invention relates to substituted isophthalic acid diamides and to their use as herbicides. Disclosed are isophthalic acid diamides having general formula (I) as herbicides. In this formula (I), Z1 and Z2 represent radicals such as al...
|
|
WO/2021/204665A1 |
The invention relates to isophthalic acid diamides having general formula (I) as herbicides. In this formula (I), X, Y and Z represent radicals such as hydrogen, alkyl and halogen. Q represents a heterocyclic ring such as tetrazolyl.
|
|
WO/2021/202914A1 |
A method for purifying lutetium includes providing a solid composition comprising ytterbium and lutetium and subliming or distilling ytterbium from the solid composition at a temperature of about 1196°C to about 3000°C to leave a lutet...
|
|
WO/2021/193410A1 |
A compound represented by formula (I) or a salt thereof, and an herbicide containing as an active ingredient at least one selected from the group consisting of said compound and salts thereof. (In formula (I), Ra and Rb each independentl...
|
|
WO/2021/180611A1 |
A method of making copper (I) 5-nitrotetrazolate (DBX-1) in isolated form comprising: a) reacting bis(ethylenediamine) copper (II) nitrotetrazolate with nitric acid or sulfuric acid to form a reaction product, subsequently b) reducing th...
|
|
WO/2021/180655A1 |
The present invention provides novel hydroquinone derivatives of formula (I), processes of preparation, as well as pharmaceutical compositions and methods of treating and/or preventing e.g. autoimmune, immunological, rheumatology, vascul...
|
|
WO/2021/175147A1 |
A prostate-specific membrane antigen (PSMA)-binding ligand conjugate and an application thereof. Specifically, a conjugate as shown in formula I: Y1-L1-Z1 (I), wherein Y1 is a chelate moiety, Z1 is a PSMA-binding ligand moiety, and L1 is...
|
|
WO/2021/162054A1 |
The purpose of the present invention is to provide a type 2 ryanodine receptor (RyR2) activity inhibitor having an excellent effect of inhibiting RyR2 activity.　An RyR2 activity inhibitor comprising a compound represented by formula (Î...
|
|
WO/2021/157861A1 |
The objective of the present invention is to provide a novel sacubitril calcium/valsartan co-crystal and co-amorphous form which overcomes the low stability, water solubility, and ease of formulation of sacubitril/valsartan sodium 2.5 hy...
|
|
WO/2021/145099A1 |
The objective of the present invention is to synthesize a zirconium complex by making even a low concentration of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) react with radioactive zirconium at a high reaction rate. A...
|
|
WO/2021/142258A1 |
The present disclosure relates to macrocyclic chelates including a macrocyclic chelating moiety of a metal complex thereof, a bifunctional linker, and a therapeutic or targeting moiety. Also disclosed are methods for preparation of the s...
|
|
WO/2021/136390A1 |
A blood coagulation factor XIa inhibitor of formula I, a pharmaceutical composition containing same, a preparation method therefor, and use thereof in preparation of drugs for prevention or treatment of thrombosis and embolism-related di...
|
|
WO/2021/123383A1 |
The present invention provides a novel method for removal of gadolinium ions from a solution comprising gadolinium complexed with DOTA. The method of the invention is relatively straightforward and cost-efficient compared with known meth...
|
|
WO/2021/123036A1 |
The present invention relates to use of a chelating compound (I) for chromatographic separation of rare earth elements, actinides, and/ or s-, p- and d-block metals, and to a method of chromatographic separation of chelates of rare earth...
|
|
WO/2021/123162A1 |
The present disclosure relates to a cocrystal of pterostilbene and a coformer capable to form hydrogen bond interactions, to a process for the preparation thereof, and to its use as a medicament or a dietary supplement. The present discl...
|
|
WO/2021/116165A1 |
The invention relates to a process for the one-step preparation and isolation of a protected DO3A such as DO3A-tri-tert-butyl ester as a solid salt.
|
|
WO/2021/118885A1 |
The present invention provides a novel compound of the formula: methods of making this compound, methods of using this compound for pretargeted imaging, and preparations of such formulations.
|
|
WO/2021/113921A1 |
The present invention relates to methods of diagnosis and therapy for neurodegenerative diseases and disorders.
|
|
WO/2021/110076A1 |
The present invention belongs to the field of medicinal chemistry and relates to oxamide derivatives, a preparation method therefor and the use thereof in medicine. In particular, provided is a compound of formula (I) or a stereoisomer, ...
|
|
WO/2021/111464A1 |
Disclosed herein is a process for the preparation and purification of Valsartan. The process according to the invention is capable of removing the toxic nitroamine impurities and providing substantially pure Valsartan.
|
|
WO/2021/102569A1 |
This disclosure relates generally to cannabinoid derivatives of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives for the treatment of conditions associated with cannabinoid receptor.
|
|
WO/2021/102568A1 |
This disclosure relates generally to cannabinoid derivatives having the structural formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives. In some embodiments, R1 is - CH2CH=C(CH3)2, R2...
|
|
WO/2021/094505A1 |
The present invention relates to compounds Formula (I) wherein Q, R2, R3 and R4 are as defined herein. The invention further relates to compositions comprising said compounds, and methods of controlling weeds using said compounds and/or ...
|
|
WO/2021/094763A1 |
The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, A compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, (I) wherein: Z is a group of formu...
|
